Viewray (NASDAQ:VRAY) Earns Buy Rating from Mizuho

Share on StockTwits

Mizuho reaffirmed their buy rating on shares of Viewray (NASDAQ:VRAY) in a research report sent to investors on Tuesday morning, AnalystRatings.com reports. The brokerage currently has a $9.00 target price on the stock.

A number of other brokerages have also recently issued reports on VRAY. Northland Securities reaffirmed a buy rating and set a $5.00 target price on shares of Viewray in a research report on Monday, August 19th. Piper Jaffray Companies set a $6.00 price objective on shares of Viewray and gave the stock a buy rating in a research note on Tuesday, October 15th. Jefferies Financial Group decreased their price objective on shares of Viewray from $14.00 to $7.00 and set a buy rating for the company in a report on Friday, August 9th. Morgan Stanley set a $5.00 target price on shares of Viewray and gave the company a hold rating in a research note on Monday, August 12th. Finally, BidaskClub upgraded shares of Viewray from a sell rating to a hold rating in a report on Thursday, November 21st. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $7.30.

Shares of NASDAQ:VRAY opened at $4.44 on Tuesday. Viewray has a fifty-two week low of $2.12 and a fifty-two week high of $9.76. The business has a 50-day moving average of $2.83 and a two-hundred day moving average of $5.55. The stock has a market capitalization of $441.36 million, a P/E ratio of -4.53 and a beta of 1.09. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.70 and a quick ratio of 2.58.

Viewray (NASDAQ:VRAY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. Viewray had a negative return on equity of 75.41% and a negative net margin of 110.61%. The business had revenue of $20.90 million for the quarter, compared to analyst estimates of $20.66 million. During the same quarter in the prior year, the firm posted ($0.39) EPS. The firm’s revenue for the quarter was up 18.1% on a year-over-year basis. As a group, research analysts expect that Viewray will post -1.13 EPS for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Usca Ria LLC bought a new position in Viewray during the third quarter worth $28,000. Stifel Financial Corp bought a new position in shares of Viewray during the third quarter valued at $39,000. Bank of Montreal Can boosted its stake in shares of Viewray by 4,390.1% in the 2nd quarter. Bank of Montreal Can now owns 5,882 shares of the company’s stock valued at $52,000 after purchasing an additional 5,751 shares in the last quarter. Raymond James Trust N.A. acquired a new stake in shares of Viewray in the 3rd quarter valued at $86,000. Finally, Allworth Financial LP grew its holdings in shares of Viewray by 587.8% in the 3rd quarter. Allworth Financial LP now owns 32,594 shares of the company’s stock worth $95,000 after purchasing an additional 27,855 shares during the last quarter.

About Viewray

ViewRay, Inc designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Further Reading: What is a Call Option?

Analyst Recommendations for Viewray (NASDAQ:VRAY)

Receive News & Ratings for Viewray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viewray and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.